Verona Pharma plc

NasdaqGM:VRNA 주식 보고서

시가총액: US$2.9b

Verona Pharma 관리

관리 기준 확인 3/4

Verona Pharma CEO는 Dave Zaccardelli, Feb2020 에 임명되었습니다 의 임기는 4.75 년입니다. 총 연간 보상은 $ 6.60M, 12.4% 로 구성됩니다. 12.4% 급여 및 87.6% 보너스(회사 주식 및 옵션 포함). 는 $ 54.39M 가치에 해당하는 회사 주식의 1.86% 직접 소유합니다. 54.39M. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 5.6 년입니다.

주요 정보

Dave Zaccardelli

최고 경영자

US$6.6m

총 보상

CEO 급여 비율12.4%
CEO 임기4.8yrs
CEO 소유권1.9%
경영진 평균 재임 기간2.7yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

Verona Pharma: A Post FDA Approval Analysis

Sep 10

Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Aug 10
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst

Jun 20

Verona Pharma: Key Inflection Point Directly Ahead

May 23

Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?

Apr 26
Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?

Verona Pharma: A Few Points From The Bull And Bear Case

Feb 15

Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Jan 26
Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data

Jan 19

Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?

Oct 12
Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?

Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?

Jun 27
Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?

Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?

Mar 10
Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?

Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?

Dec 02
Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

Sep 13

Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials

Aug 19

Verona Pharma GAAP EPS of -$0.04 beats by $0.23

Aug 09

Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster

Feb 04

Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%

Feb 02

Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19

Jan 14

Verona Pharma EPS beats by $0.15

Oct 29

CEO 보상 분석

Dave Zaccardelli 의 보수는 Verona Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$154m

Jun 30 2024n/an/a

-US$125m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$7mUS$820k

-US$54m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$5mUS$525k

-US$69m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$55m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$1mUS$273k

-US$56m

Sep 30 2021n/an/a

-US$57m

Jun 30 2021n/an/a

-US$87m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020US$18mUS$229k

-US$65m

보상 대 시장: Dave 의 총 보상 ($USD 6.60M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.60M ).

보상과 수익: 회사가 수익성이 없는 동안 Dave 의 보상이 증가했습니다.

CEO

Dave Zaccardelli (60 yo)

4.8yrs

테뉴어

US$6,597,473

보상

Dr. David S. Zaccardelli, also known as Dave, Pharm D., has been President, Chief Executive Officer and Executive Director of Verona Pharma plc since February 1, 2020. Dr. Zaccardelli has been Director of...

리더십 팀

이름위치테뉴어보상소유권
David Zaccardelli
President4.8yrsUS$6.60m1.86%
$ 54.4m
Mark Hahn
Chief Financial Officer4.7yrsUS$6.18m1.72%
$ 50.3m
Kathleen Rickard
Chief Medical Officer5.8yrsUS$1.98m0.36%
$ 10.5m
Andrew Fisher
General Counselless than a year데이터 없음데이터 없음
Victoria Stewart
Director of Communicationsno data데이터 없음데이터 없음
Matthew Casbon
VP of Sales2.3yrs데이터 없음데이터 없음
Ostra Jewell
Senior Vice President of Human Resources2.2yrs데이터 없음데이터 없음
Tara Rheault
Chief Development Officerno data데이터 없음데이터 없음
Christopher Martin
Chief Commercial Officerno data데이터 없음데이터 없음
Caroline Diaz
Senior Vice President of Regulatory Affairs3.1yrs데이터 없음데이터 없음
Kavita Aggarwal
Senior Vice President of Medical Affairs1.8yrs데이터 없음데이터 없음
Benjamin Harber
Company Secretaryno data데이터 없음데이터 없음

2.7yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: VRNA 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
David Zaccardelli
President4.8yrsUS$6.60m1.86%
$ 54.4m
Mahendra Gopaldas Shah
Independent Non-Executive Director8.3yrsUS$224.83k0.011%
$ 325.7k
Martin Edwards
Independent Non-Executive Director5.6yrsUS$219.74k0.022%
$ 645.5k
Kenneth Cunningham
Independent Non-Executive Director9.2yrsUS$232.47k0.010%
$ 296.8k
David Ebsworth
Independent Non-Executive Chairman9.9yrsUS$330.50k0.14%
$ 4.1m
Anders Ullman
Independent Non-Executive Director9.2yrsUS$219.74k0.051%
$ 1.5m
Vikas Sinha
Independent Non-Executive Director8.2yrsUS$238.83k0.011%
$ 331.8k
Christina Ackermann
Non-Executive Director1.2yrsUS$267.91k0.0064%
$ 186.8k
Lisa Deschamps
Independent Non-Executive Director3.7yrsUS$223.56k0.011%
$ 313.4k
James Brady
Independent Non-Executive Director2.7yrsUS$226.10k0%
$ 0
Michael Austwick
Independent Non-Executive Directorless than a year데이터 없음데이터 없음

5.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: VRNA 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.